{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T13:40:34Z","timestamp":1762782034889},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13256-016-1175-1","type":"journal-article","created":{"date-parts":[[2017,1,13]],"date-time":"2017-01-13T07:09:03Z","timestamp":1484291343000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Glucagon-like peptide-1 analogues - an efficient therapeutic option for the severe insulin resistance of lipodystrophic syndromes: two case reports"],"prefix":"10.1186","volume":"11","author":[{"given":"Joana","family":"Oliveira","sequence":"first","affiliation":[]},{"given":"Eva","family":"Lau","sequence":"additional","affiliation":[]},{"given":"Davide","family":"Carvalho","sequence":"additional","affiliation":[]},{"given":"Paula","family":"Freitas","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2017,1,13]]},"reference":[{"issue":"10","key":"1175_CR1","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.revmed.2012.11.008","volume":"34","author":"L Fardet","year":"2013","unstructured":"Fardet L, Vigourox C, Capeau J. Syndromes lipodystrophiques. Rev Med Interne. 2013;34(10):614\u201322.","journal-title":"Rev Med Interne"},{"issue":"6","key":"1175_CR2","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s11892-013-0431-7","volume":"13","author":"C Vatier","year":"2013","unstructured":"Vatier C, Bidault G, Briand N, Gu\u00e9nantin AC, Teyssi\u00e8res L, Lascols O, Capeau J, Vigouroux C. What the Genetics of Lipodystrophy Can Teach Us About Insulin Resistance and Diabetes. Curr Diab Rep. 2013;13(6):757\u201367.","journal-title":"Curr Diab Rep"},{"issue":"1","key":"1175_CR3","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/jhg.2013.107","volume":"59","author":"T Nolis","year":"2014","unstructured":"Nolis T. Exploring the pathophysiology behind the more common genetic and acquired lipodystrophies. J Hum Genet. 2014;59(1):16\u201323.","journal-title":"J Hum Genet"},{"issue":"3","key":"1175_CR4","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1172\/JCI7901","volume":"105","author":"O Gavrilova","year":"2000","unstructured":"Gavrilova O, Marcus-Samuels B, Graham D, Kim JK, Shulman GI, Castle AL, Vinson C, Eckhaus M, Reitman ML. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J Clin Invest. 2000;105(3):271\u20138.","journal-title":"J Clin Invest"},{"issue":"10","key":"1175_CR5","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S1043-2760(00)00309-X","volume":"11","author":"ML Reitman","year":"2000","unstructured":"Reitman ML, Arioglu E, Gavrilova O, Taylor SI. Lipoatrophy revisited. Trends Endocrinol Metab. 2000;11(10):410\u20136.","journal-title":"Trends Endocrinol Metab"},{"key":"1175_CR6","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1210\/jc.2012-1140","volume":"97","author":"N Abate","year":"2012","unstructured":"Abate N. Adipocyte maturation arrest: a determinant of systemic insulin resistance to glucose disposal. J Clin Endocrinol Metab. 2012;97:760\u20133.","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"1175_CR7","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4158\/endp.19.1.v767575m65p5mr06","volume":"19","author":"Y Handelsman","year":"2013","unstructured":"Handelsman Y, Oral EA, Bloomgarden ZT, Brown RJ, Chan JL, Einhorm D, Garber AJ, Garg A, Garvey WT, Grunberger G, Henry RR, Lavin N, Tapiador CD, Weyer C. The Clinical Aproach to the Detection of Lypodistrophy \u2013 an AACE Consensus Statement. Endocr Pract. 2013;19(1):107\u201316.","journal-title":"Endocr Pract"},{"issue":"3","key":"1175_CR8","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1677\/JOE-10-0272","volume":"207","author":"I Huang-Doran","year":"2010","unstructured":"Huang-Doran I, Sleigh A, Rochford JJ, O\u2019Rahilly S, Savage DB. Lipodystrophy: metabolic insights from a rare disorder. J Endocrinol. 2010;207(3):245\u201355.","journal-title":"J Endocrinol"},{"issue":"12","key":"1175_CR9","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/j.1463-1326.2009.01158.x","volume":"11","author":"J Jendle","year":"2009","unstructured":"Jendle J, Nauck MA, Matthews DR, Frid A, Hermansen K, D\u00fcring M, Zdravkovic M, Strauss BJ, Garber AJ. LEAD-2 and LEAD-3 Study Groups. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab. 2009;11(12):1163\u201372.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"1175_CR10","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00592-014-0710-z","volume":"52","author":"S Morano","year":"2015","unstructured":"Morano S, Romagnoli E, Filardi T, Nieddu L, Mandosi E, Fallarino M, Turinese I, Dagostino MP, Lenzi A, Carnevale V. Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study. Acta Diabetol. 2015;52(4):727\u201332.","journal-title":"Acta Diabetol"},{"key":"1175_CR11","doi-asserted-by":"crossref","first-page":"E318","DOI":"10.1152\/ajpendo.00191.2010","volume":"299","author":"ET Parlevliet","year":"2010","unstructured":"Parlevliet ET, de Leeuw van Weenen JE, Romijn JA, Pijl H. GLP-1 treatment reduces endogenous insulin resistance via activation of central GLP-1 receptors in mice fed a high-fat diet. Am J Physiol Endocrinol Metab. 2010;299:E318\u201324.","journal-title":"Am J Physiol Endocrinol Metab."},{"key":"1175_CR12","doi-asserted-by":"publisher","first-page":"706416","DOI":"10.1155\/2015\/706416","volume":"2015","author":"H Jinnouchi","year":"2015","unstructured":"Jinnouchi H, Sugiyama S, Yoshida A, Hieshima K, Kurinami N, Suzuki T, Miyamoto F, Kajiwara K, Matsui K, Jinnouchi T. Liraglutide, a Glucagon-Like Peptide-1 Analog, Increased Insulin Sensitivity Assessed by Hyperinsulinemic-Euglycemic Clamp Examination in Patients with Uncontrolled Type 2 Diabetes Mellitus. J Diabetes Res. 2015;2015:706416. doi: 10.1155\/2015\/706416 . 8 pages.","journal-title":"J Diabetes Res."},{"key":"1175_CR13","doi-asserted-by":"publisher","first-page":"524517","DOI":"10.1155\/2014524517","volume":"2014","author":"H Wu","year":"2014","unstructured":"Wu H, Sui C, Xu H, Xia F, Zhai H, Zhang H, Weng W, Han B, Du S, Lu Y. The GLP-1 Analogue Exenatide Improves Hepatic and Muscle Insulin Sensitivity in Diabetic Rats: Tracer Studies in the Basal State and during Hyperinsulinemic-Euglycemic Clamp. J Diabetes Res. 2014;2014:524517. doi: 10.1155\/2014524517 . 10.","journal-title":"J Diabetes Res"},{"key":"1175_CR14","doi-asserted-by":"crossref","first-page":"d7771","DOI":"10.1136\/bmj.d7771","volume":"344","author":"T Vilsb\u00f8ll","year":"2012","unstructured":"Vilsb\u00f8ll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771.","journal-title":"BMJ."},{"issue":"6","key":"1175_CR15","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.2337\/dc06-2593","volume":"30","author":"T Vilsb\u00f8ll","year":"2007","unstructured":"Vilsb\u00f8ll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courreges JP, Verhoeven R, Buganova I, Madsbad S. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care. 2007;30(6):1608\u201310.","journal-title":"Diabetes Care"},{"issue":"4","key":"1175_CR16","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1089\/dia.2012.0328","volume":"15","author":"KM Pantalone","year":"2013","unstructured":"Pantalone KM, Faiman C. Liraglutide Effective in the Severely Insulin-Resistant Patient with Type 2 Diabetes Requiring U-500 Insulin: A Case Report. Diabetes Technol Ther. 2013;15(4):342\u20133.","journal-title":"Diabetes Technol Ther"},{"key":"1175_CR17","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00228-015-1868-1","volume":"71","author":"M Jensterle","year":"2015","unstructured":"Jensterle M, Pir\u0161 B, Gori\u010dar K, Dol\u017ean V, Jane\u017e A. Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight lowering potential of liraglutide in obese women with PCOS: a pilot study. Eur J Clin Pharmacol. 2015;71:817\u201324.","journal-title":"Eur J Clin Pharmacol."}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-016-1175-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T10:15:15Z","timestamp":1568715315000},"score":1,"resource":{"primary":{"URL":"http:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-016-1175-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,13]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1175"],"URL":"https:\/\/doi.org\/10.1186\/s13256-016-1175-1","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,13]]},"article-number":"12"}}